ASRI PUTRI PRATIWI, 051511133007 (2019) PERUBAHAN IL-1β PADA PENGGUNAAN GLUKOSAMIN SEBAGAI ADJUVAN TERAPI MELOXICAM DENGAN MO DEL TIKUS O STEO ARTHRITIS. Skripsi thesis, Universitas Airlangga.

	Text FF.FK.39-19 Pra p abstrak.pdf Download (101kB)
	Text FF.FK.39-19 Pra p daftar isi.pdf Download (111kB)
	Text FF.FK.39-19 Pra p daftar pustaka.pdf Download (189kB)
	Text (FULLTEXT) FF.FK.39-19 Pra p.pdf Restricted to Registered users only until 19 November 2022. Download (2MB) | Request a copy

Abstract

Osteoarthritis is the most common type of arthritis and degenerative joint disease. The pathophysiology of osteoarthritis shows that proinflammatory cytokines play an important role in cartilage damage, synovitis, and pain. Interleukin-1β (IL-1β) is the main pro-inflammatory cytokine that plays an important role in the condition of osteoarthritis. Meloxicam and glucosamine are known to reduce IL-1β. The use of glucosamine as an adjuvant to meloxicam therapy is expected to inhibit the development of inflammatory osteoarthritis. The osteoarthritis model in rat was made by injection of monosodium iodoacetate (MIA) intra-articular and observed for 21 days. Furthermore, to test the ability of glucosamine as an adjuvant of meloxicam therapy in reducing IL-1β, was done by combine meloxicam 1 mg/kgBB with glucosamine at a dose of 125 mg/kgBB; 250 mg/kgBB; 500 mg/kgBB orally for 28 days. Response to hyperalgesia and knee diameter was measured on days 0, 7, 14, 21, 28, 35, 42, and 49. IL-1β levels were measured on day 21st and day 49th after MIA injection MIA injection successfully induced osteoarthritis marked by a significant difference in the time of resistance to heat stimulus (p <0.01) and a significant increase in knee diameter (p <0.01). On 21st day, IL-1β levels showed a significant decrease in MIA injection (p =0.05). The administration of meloxicam and glucosamine did not show a significant decreases in knee diameter (p >0.10), but was able to significantly increases the resistance time to heat stimulus (p <0.01). After administration of therapy, IL-1β levels also showed a significant decreased compared to before administration of therapy (p <0.01). The decreasing IL-1β levels after the use of glucosamine as an adjuvant of meloxicam therapy may be caused by the synergistic mechanism of meloxicam and glucosamine.

Actions (login required)

View Item